Filing Flows

Filing Flows › Niagen Bioscience (NAGE) › Who owns the stock

Who owns Niagen Bioscience (NAGE) stock

130 funds reported Niagen Bioscience (NAGE) shares in their latest 13F filings, worth $115M in all. The largest holder is Vanguard Group ($20.9M). Last quarter 57 funds added to their stakes and 77 cut them.

Largest holders of NAGE (13F)Largest holders of NAGE (13F)Vanguard Group$20.9MBlackRock$13.3MSteelPeak Wealth, LLC$10.4MVanguard Capital Management LLC$6.8MQube Research & Technologies$5.2MGeode Capital Management, LLC$4.7MUBS Group AG$4.1MGoldman Sachs Group$4.0MArrowstreet Capital, Limited Part…$3.7MVanguard Portfolio Management LLC$3.7M

Largest holders (13F)

FundSharesValueChangeQuarter
Vanguard Group3,286,498$20.9Mdecrease2025-12-31
BlackRock4,184,659$13.3Mincrease2026-06-30
SteelPeak Wealth, LLC3,577,435$10.4Mincrease2026-09-30
Vanguard Capital Management LLC2,147,018$6.8Mdecrease2026-06-30
Qube Research & Technologies1,625,016$5.2Mdecrease2026-06-30
Geode Capital Management, LLC1,478,603$4.7Mincrease2026-06-30
UBS Group AG1,283,296$4.1Mdecrease2026-06-30
Goldman Sachs Group1,262,743$4.0Mincrease2026-06-30
Arrowstreet Capital, Limited Partnership1,171,215$3.7Mdecrease2026-06-30
Vanguard Portfolio Management LLC1,166,233$3.7Mdecrease2026-06-30
State Street1,082,752$3.5Mdecrease2026-06-30
Renaissance Technologies LLC659,584$2.1Mdecrease2026-06-30
Citadel Advisors LLC630,109$2.0Mincrease2026-06-30
Dimensional Fund Advisors LP605,326$1.9Mdecrease2026-06-30
Morgan Stanley504,772$1.6Mincrease2026-06-30

Niagen Bioscience's latest quarter

Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most NAGE stock?

By the latest 13F filings: Vanguard Group ($20.9M); BlackRock ($13.3M); SteelPeak Wealth, LLC ($10.4M); Vanguard Capital Management LLC ($6.8M); Qube Research & Technologies ($5.2M).

What is the short interest in NAGE?

4,175,152 shares were sold short at the 2026-10-15 settlement, 7.77% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.